Participated · Seed · Apr 2026

Q-Factor was founded in 2026 by four leading physicists from the Weizmann Institute of Science and the Technion and had operated in stealth before its public emergence. The company is developing a full-scale quantum computer using neutral atom technology and says it has identified architectural bottlenecks in existing systems. Its stated goal is to enable continuous scalability of neutral-atom systems toward and beyond one million qubits. Founders include Prof. Nir Davidson, Prof. Ofer Firstenberg, Prof. Yoav Sagi, and Dr. Guy Raz, bringing deep academic and technical leadership to the venture. Q-Factor is backed by a $24 million Seed round and a grant from the Israel Innovation Authority, and counts institutional investors and the founders' academic institutions among its shareholders.

Participated · Series A · Dec 2025

Quantum Art was spun out of Prof. Roee Ozeri's group at the Weizmann Institute of Science and is led by CEO and co-founder Dr. Tal David, CTO Dr. Amit Ben Kish and CSO Prof. Roee Ozeri. The company focuses on trapped-ion quantum computing and has developed proprietary techniques for multi-qubit gates, scalable modular architectures, and robust quantum error correction. It is advancing a multi-core roadmap including Perspective, a planned 1,000-qubit system aimed at commercial-scale deployment. Quantum Art is transitioning toward commercialization with plans for a Quantum-as-a-Service (QaaS) platform that lets customers move from algorithm development and co-design to execution on its hardware. The company said it is expanding internationally and building partnerships to support early customer adoption while hiring to support development and business growth.

Led · Series B · May 2021

UltraSight, formerly OnSight Medical, is a Tel Aviv-based digital health company that develops an AI platform for ultrasound devices to perform real-time sonography at the point of care. Its core product provides real-time AI guidance for cardiac imaging across clinics, community hospitals, ambulances and remote settings. The company recently raised $13M in a Series B funding round. UltraSight intends to use the funds to advance U.S. clinical programs for its real-time AI guidance in a variety of care settings. Led by CEO Davidi Vortman, UltraSight aims to enable medical professionals to diagnose patients wherever they are. The company focuses on point-of-care sonography to expand access to cardiac imaging.